Baseline resting EEG measures differentiate rTMS treatment responders and non-responders

Pakin Kaewpijit; Paul B Fitzgerald; Kate Hoy; Neil W Bailey

doi:10.1101/2023.11.16.23298445

Abstract

Background Repetitive transcranial magnetic stimulation (rTMS) has been increasingly used worldwide in the treatment of depression, however, we currently lack the means to reliably predict whether patients will respond to the treatment. Recent research suggests that the neurophysiological measures of beta power and correlation dimension may have predictive potential, however, studies of beta power and correlation dimension to differentiate rTMS group response in individuals with major depression are limited.

Methods Fifty treatment-resistant patients with major depressive disorder were recruited. Forty-two participants underwent baseline resting EEG sessions and 5-8 weeks of rTMS treatments and 12 participants were responders to the treatment. Beta power and correlation dimension from baseline resting EEG were compared between responders and non-responders.

Results Responders demonstrated significantly lower beta power in baseline resting EEG, however, correlation dimension did not show a significant difference between groups.

Limitations There were a small number of responders in this study.

Conclusion Baseline resting beta power may help to differentiate responders from non-responders to rTMS treatment. However, further studies are needed with larger sample sizes.

Competing Interest Statement

In the last 3 years PBF has received equipment for research from Neurosoft, Nexstim and Brainsway Ltd. He has served on scientific advisory boards for Magstim and LivaNova and received speaker fees from Otsuka. He has also acted as a founder and board member for TMS Clinics Australia and Resonance Therapeutics. KEH is a founder of Resonance Therapeutics. The other authors declare that they have no conflicts of interest.

Clinical Trial

ACTRN12610000998044

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Alfred Hospital and Monash University's ethics committees gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

Funding Information PBF is supported by a National Health and Medical Research Council of Australia Investigator grant (1193596). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflict of Interest In the last 3 years PBF has received equipment for research from Neurosoft, Nexstim and Brainsway Ltd. He has served on scientific advisory boards for Magstim and LivaNova and received speaker fees from Otsuka. He has also acted as a founder and board member for TMS Clinics Australia and Resonance Therapeutics. KEH is a founder of Resonance Therapeutics. The other authors declare that they have no conflicts of interest.